Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy

Abstract

The novel J-CAPRA is the first risk instrument developed and validated for patients undergoing PADT. It is applicable to those with both localized and advanced disease, and performs well in diverse populations.